Pyxis Oncology Announces Participation in Upcoming Investor Conferences

BOSTON, August 29, 2024 -- Announcing its upcoming participation in two key investor conferences, Pyxis Oncology, Inc. (PYXS), a clinical stage biotechnology firm, is garnering attention in the investment community. With a focus on the development of innovative therapeutic options aiming to combat difficult-to-treat cancers, Pyxis Oncology's presence at these events is especially newsworthy for stakeholders and potential investors.

Conference Engagement Highlights Corporate Progress

At the forefront of these engagements, Pyxis Oncology's President and Chief Executive Officer, Dr. Lara S. Sullivan, will represent the company. These investor events provide an important platform for Pyxis Oncology to showcase its strategic initiatives and pipeline developments to an audience of institutional investors, analysts, and industry experts.

About Pyxis Oncology, Inc.

Based in Cambridge, Massachusetts, Pyxis Oncology, Inc. PYXS operates as a trailblazing preclinical biotechnology entity. The company's focus lies in the creation of antibody-drug conjugates (ADC) and monoclonal antibody (mAb) immunotherapies. These advanced treatment modalities are designed to address a spectrum of cancers that currently have limited options available. With its commitment to innovation, Pyxis Oncology aspires to alter the oncology treatment landscape significantly.

Pyxis, Oncology, Conferences